Literature DB >> 10660343

Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.

A H Walker1, J M Jaffe, S Gunasegaram, S A Cummings, C S Huang, H D Chern, O I Olopade, B L Weber, T R Rebbeck.   

Abstract

CYP3A4 is involved in the metabolism of numerous biologically active compounds, including testosterone. A genetic variant located in the P450NF (nifedipine) specific element (NFSE) has been identified that disrupts a transciptional regulatory element located in the 5' regulatory region of CYP3A4. The CYP3A4 variant (CYP3A4-V) is associated with the clinical presentation of prostate cancer. There are significant differences in CYP3A4 metabolism and rates of prostate cancer across ethnic groups that may be associated with CYP3A4 genotypes. Therefore, we estimated the frequency of the CYP3A4 variant in three ethnic groups with different prostate cancer incidence rates. The frequency (q) of CYP3A4-V was significantly different (p<0.0001) in African Americans (q=0.53), U.S. Caucasians (q=0.09), and Taiwanese (q=0.0). CYP3A4-V segregated in a Mendelian manner in one large African American family, and 7 of 16 (44%) biologically unrelated "marry-ins" carried a CYP3A4 variant allele. Reflecting population-specific prostate cancer incidence rates, our results suggest a high frequency of this variant in African Americans compared with U.S. Caucasians and Taiwanese.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10660343

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  27 in total

Review 1.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

Review 2.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

3.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

5.  Shielded from the real world: perspectives on Internet cancer support groups by Asian Americans.

Authors:  Eun-Ok Im; Bokim Lee; Wonshik Chee
Journal:  Cancer Nurs       Date:  2010 May-Jun       Impact factor: 2.592

Review 6.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

7.  Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.

Authors:  T M Bosch; V D Doodeman; P H M Smits; I Meijerman; J H M Schellens; J H Beijnen
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

9.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

Authors:  Christian Friedrich; Stephan Glund; Dominick Lionetti; C James Kissling; Julian Righetti; Sanjay Patel; Ulrike Graefe-Mody; Silke Retlich; Hans-Juergen Woerle
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.